Patents
Ourself® proprietary technologies, including Tiered-Release Vesicle™ (TRV™) delivery technology and MI9™ peptide technology, are protected by issued patents in the United States and key international markets, with additional patents and applications pending globally.
Certain Ourself® products and technologies (GLO Pharma LLC) are protected by patents in the United States and other jurisdictions.
The following Ourself® products, platforms and technology are protected by patents in the United States and elsewhere. This website page is provided to satisfy virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act. In accordance with Section 287(a) of Title 35 of the United States Code, notice is given. Additional patents and patent applications may also be pending in the United States and internationally.
Tiered-Release Vesicle™ (TRV™) Delivery Technology
Used in certain and future Ourself® cosmetic products including:
- Advanced Regenerative Serum
- Advanced Regenerative Eye Serum
- Complexion Brightening Serum
- Replenishing Lip Filler
One or more of the following patents may apply:
| US 11,801,221 |
| US 12,544,332 |
| US 12,544,333 |
| CN ZL 2020800813833 |
| JP 7767274 |
| HK HK40081351 |
| MY MY-211853-A |
MI9™ Peptide Technology
Used in Complexion Brightening Serum
Protected by:
| US 12,162,956 |